Trodelvy® Improved Progression-Free Survival by 34% in Heavily Pre-Treated HR+/HER2- Metastatic Breast Cancer Patients Pharmaceutical Investing
Bristol Myers Squibb Withdraws Supplemental Biologics License Application for Reblozyl® for Non-transfusion Dependent Beta Thalassemia Pharmaceutical Investing
Yescarta® CAR T-cell Therapy Demonstrates Consistent Survival Outcomes and Safety in Real-World Setting Regardless of Race and Ethnicity Pharmaceutical Investing
Aurinia Presents Data Demonstrating LUPKYNIS® is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations Pharmaceutical Investing
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company Pharmaceutical Investing
Bristol Myers Squibb Announces Topline Results Showing Treatment with Orencia Improved Survival in People Hospitalized with COVID-19 Pharmaceutical Investing
Gilead Sciences Appoints Stacey Ma, PhD as Executive Vice President, Pharmaceutical Development and Manufacturing Pharmaceutical Investing
